Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070870 | 0.84 | MAOB (0.43) | LMNATSHRSMN1; SMN2HTT | |
| SCHEMBL4068011 | 0.83 | CHRM5 (0.39) | G6PC1 | |
| SCHEMBL2227055 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4POLBMAPTMAPK1 | |
| SCHEMBL9129445 | 0.76 | CHRNA7 (0.57) | CHRNB2CHRNA4CHRNA7GAAKCNA5 | |
| SCHEMBL4069054 | 0.76 | CHRNB2 (0.57) | CHRNB2CHRNA4POLBMAPTMAPK1 | |
| SCHEMBL14415500 | 0.76 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7KCNA5KCNN4 | |
| SCHEMBL8726941 | 0.75 | LTA4H (0.52) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL21871562 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA7KCNA5KCNN4 | |
| SCHEMBL4067161 | 0.72 | NOTUM (0.47) | CHRNB2CHRNA4POLBMAPTMAPK1 | |
| SCHEMBL4067661 | 0.72 | CHRM2 (0.48) | POLBMAPK1LMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | CHRNB2 279/4885CHRNA4 207/4885POLB 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.